Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging

BACKGROUND: Glucagon‐like peptide‐1 receptor agonists may be a treatment option in patients with non‐alcoholic fatty liver disease (NAFLD). AIMS: To investigate the effects of semaglutide on liver stiffness and liver fat in subjects with NAFLD using non‐invasive magnetic resonance imaging (MRI) meth...

Descripción completa

Detalles Bibliográficos
Autores principales: Flint, Anne, Andersen, Grit, Hockings, Paul, Johansson, Lars, Morsing, Anni, Sundby Palle, Mads, Vogl, Thomas, Loomba, Rohit, Plum‐Mörschel, Leona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Randomised Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292692/
https://www.ncbi.nlm.nih.gov/pubmed/34570916
http://dx.doi.org/10.1111/apt.16608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292692/
https://www.ncbi.nlm.nih.gov/pubmed/34570916
http://dx.doi.org/10.1111/apt.16608

Ejemplares similares